Which Small-Cap Biotech Has The Most Comprehensive, Yet Undervalued Immunotherapy Platform In Development? Print E-mail
By David Ibrahim, MarketScanners   
Monday, 03 November 2014 23:20
icon_closerlookThe National Cancer Institute (NCI) spends upwards of $4.9 billion each year on cancer research. While the larger research entities like NCI get all the press coverage and media attention, it's the smaller highly specialized organizations working behind the scenes that are the real heroes.
Hope for Alcohol Damaged Liver Patients Print E-mail
By Marilyn Mullen   
Monday, 03 November 2014 20:07
  Hope for alcohol damaged liver patients.
Q&A with Provectus Biopharmaceutical’s COO/CFO, Peter Culpepper Print E-mail
By Dusty Garza   
Thursday, 16 October 2014 15:18
Provectus Biopharmaceuticals, Inc., (NYSE MKT: PVCT) specializes in developing oncology and dermatology therapies. PV-10, its novel investigational drug for cancer, is designed for injection into solid tumors (intralesional administration), thereby reducing potential for systemic side effects.
Rexahn's New Nanotechnology Patent Creates Next-Generation Docetaxel, Gemcitabine, and Cisplatin Print E-mail
By Sharon di Stefano   
Wednesday, 08 October 2014 18:11
Targeted cancer therapy is a revolution in drug company research, and Rexahn Pharmaceuticals, Inc. (RNN:NYSE MKT), recent recipient of a notice of allowance from the US Patent and Trademark Office for a new delivery platform,  might one day join the league of bigger players.
Biotech Investors Gamble on Ebola Stocks Print E-mail
By M.E.Garza   
Tuesday, 07 October 2014 04:02
The recent outbreaks of Ebola in Africa and the first case found in the U.S. have also heightened the FDA’s awareness of disease outbreaks and the need for stronger safety measures, but nothing gets investors salivating more that and
constant media attention.
Akebia Therapeutic' Trade Pattern and

Error. Page cannot be displayed. Please contact your service provider for more details. (26)

Print E-mail
By M.E.Garza   
Thursday, 02 October 2014 07:27
icon_tradethesisAnemia is common among patients with Chronic Kidney Disease (CKD) and end stage renal disease (ESRD). It is estimated that about 1.8 million people in the U.S. have anemia associated with chronic kidney disease.
United Therapeutics Points to Pluristem's PLX-PAD as its Most Transformative Product Print E-mail
By Sharon di Stefano   
Wednesday, 17 September 2014 04:37
icon_HeatingUpPulmonary arterial hypertension (PAH), a progressive and life threatening illness that regrettably takes a back seat to cardiovascular disease where research is concerned, is incurable and fatal. Characterized by high blood pressure in the arteries of the lungs, the heart becomes overworked, leading to its failure. Only a handful of drugs have been developed for PAH despite its huge market size.
Oramed’s Insulin Pill Superior to New Diabetes Drugs Gaining Approval Print E-mail
By Staff and Wire Reports   
Thursday, 11 September 2014 03:47
Pharmaceutical companies are adept at rolling out new classes of drugs, despite potential harmful side effects, and Eli Lilly and Co. (LLY:NYSE) is no exception.
Is Exact Sciences still a buy at these prices? Print E-mail
By Staff and Wire Reports   
Wednesday, 20 August 2014 09:17
icon_closerlook As biotech investors may know, the FDA approved a new genetic test from EXACT Sciences Corporation (NASDAQ:EXAS) that can help diagnose colon cancer.
Are "Toxic Financings" Slaying Small Retail Investors? Print E-mail
By Staff and Wire Reports   
Tuesday, 19 August 2014 04:32
Ironridge GlobalWhat do publicly traded biotech companies like Genetic Technologies (NASDAQ::GENE), Rosetta Genomics (NASDAQ::ROSG), MEI Pharma Inc(NASDAQ::MEIP), Advaxis, Inc.(NASDAQ::ADXS), Amarantus Bioscience (OTCMKTS:AMBS), Pressure Biosciences (OTCMKTS:PBIO), Uluru Inc. (OTCMKTS:ULUR), PositiveID Corporation (OTCMKTS:PSID), Cord Blood America Inc.(OTCMKTS:CBAI) and IntelliCell BioSciences, Inc. (OTCMKTS:SVFC) all have in common? 
<< Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >>

Page 9 of 55